Movement Alert｜ResMed After-Hours Rise 6.4%, fiscal Q1 earnings and revenue beat expectations

Market Focus10-30

On October 30, ResMed rose 6.4% in After-Hours Trading, with shares trading near $270.05 and turnover of $6.26 million.

The move followed fiscal first-quarter results that exceeded Wall Street expectations. ResMed reported adjusted earnings of $2.91 per diluted share, up from $2.55 a year earlier, while revenue increased to $1.42 billion from $1.34 billion. Consensus forecasts had called for adjusted EPS of about $2.67-$2.69 and revenue of roughly $1.39 billion.

Management also issued fiscal 2027 guidance for non-GAAP EPS of $12.00 to $12.25 on revenue of $5.75 billion to $5.85 billion, broadly around market expectations. The earnings beat came after analysts had entered the print with a generally constructive stance, with several firms raising price targets in recent weeks and consensus ratings remaining skewed toward overweight.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment